GILD — Gilead Sciences, Inc.

The market is focused on the underlying operating beat, not the headline GAAP loss: Q2 2026 revenue rose ~10% YoY to $7.80B vs. ~$7.4B expected, management raised FY 2026 product sales guidance to ~$30.25B, Biktarvy remains durable, and Bixlenvo was approved on August 27, 2026. The large IPR&D charge is being treated as a one-time pipeline-investment cost rather than a red flag, and Wall Street consensus is Buy.

Revenue is inflecting higher: YoY growth went from ~3.0% in Q3 2025 to ~4.7% in Q4 2025, ~4.4% in Q1 2026, and ~10.2% in Q2 2026 ($7.80B vs. $7.08B). Excluding the Q2 2026 IPR&D write-down, operating margins have been consistently strong, roughly 34–43% over the past four quarters. Reported Q2 GAAP EPS of -$8.45 and the ~50% sequential drop in equity are accounting charges, not cash losses: TTM FCF is ~$13.0B, and Q2 2026 operating cash flow of $3.57B was 4.3x the year-ago quarter. This is an acceleration in cash generation with a one-time earnings distortion, not a structural decline.

Reported TTM P/E of -57.3x and PEG of 0.38 are unusable because GAAP EPS is negative. Normalizing for the one-time IPR&D charge, 2026 EPS is around $6.90–7.00, putting the stock at roughly 21x forward earnings—not cheap versus big-pharma averages or Gilead's own normal mid-teens multiple. Price/sales of 6.1x is ~50% above its 5-year average of 4.0x. So while the deterministic model labels valuation neutral vs. own history, on a realistic normalized basis the stock is fairly valued at best and modestly expensive at worst.

The stock has rallied ~37% off the 52-week low and now sits just below the consensus target, so the market is paying for Bixlenvo/lenacapavir and Trodelvy optionality rather than waiting for proof. With price at $148.86 vs. consensus target $151.25, the visible good news is largely in the tape; further upside requires pipeline execution. If normalized EPS reaches $7.50–8.00, 19–20x supports $142–160; if HIV competition or Trodelvy uptake disappoints, the low-$120s cautious-target zone is the realistic downside.

As of 2026-08-27, RSI(14) is 69.1, just below overbought, and price is +6.9% above the 20-day SMA, +11.4% above the 50-day SMA, and +11.4% above the 200-day SMA. The trend is strongly up but stretched, increasing pullback risk. Better entry timing would be a dip toward the 20-day SMA around $139 or the 50-day around $134 rather than chasing at $149.

• Rotation into defensive large-cap biopharma favors GILD given its low beta of 0.34, 2.6% dividend yield, and stable HIV cash flows.
• FDA and EMA accelerated pathways are supportive, including Bixlenvo approval and expanded Trodelvy indications in Europe.
• US IRA drug-price negotiation remains a long-term overhang for HIV and oncology pricing.
• Interest rates matter: GILD's 2.6% dividend and high free cash flow make it a quasi-bond proxy; lower rates increase relative appeal.
• Aggressive BD/pipeline spending (the source of the IPR&D charge) adds both upside optionality and capital-allocation risk.

• Commercial uptake of Bixlenvo and the broader lenacapavir-based HIV franchise following the August 27, 2026 FDA approval.
• Trodelvy first-line mTNBC expansion in Europe and ongoing oncology data readouts.
• Management commentary at the Wells Fargo, Cantor, and Morgan Stanley healthcare conferences in September 2026.
• Q2 2026 already beat revenue estimates and raised guidance; next quarterly filing will test whether the acceleration continues.

• The Q2 2026 net loss of -$10.5B from IPR&D charges shows the scale of pipeline bets; poor execution or impairments would hit book value and credibility.
• HIV franchise concentration: Biktarvy faces eventual patent loss and competition from next-gen HIV drugs, while IRA negotiation could pressure pricing.
• Valuation is stretched: ~21x normalized forward earnings, RSI near 69, and price above all key moving averages leaves little margin of safety.
• Balance sheet leverage: long-term debt of ~$23.8B and debt/equity of 2.2x are elevated, made worse by the equity hit from the IPR&D charge.

GILD is a good business at a fair-to-full price. The HIV franchise generates durable, high-margin cash flow, Q2 showed accelerating revenue, and Bixlenvo/Trodelvy add genuine growth options. But at ~$149 and roughly 21x normalized earnings, near the consensus target and technically overbought, the easy money has been made; I lean positive for long-term holders but would prefer to build a position on a pullback rather than chase here.

Applying a 20.5x multiple to normalized 2026 EPS of ~$6.95 (2026E revenue of ~$30.7B x ~27.7% net margin / ~1.24B shares) gives ~$142.50; a simplified DCF on ~$13B normalized FCF with a 9% discount rate and 2% terminal growth lands in the same area.